uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease; AMT-060, which is in Phase I/II clinical trial for the treatment of hemophilia B; AMT-180 for the treatment of hemophilia A; AMT-190, an IV-administered adeno-associated virus (AAV) 5-based gene therapy for the treatment of Fabry disease; and AMT-150, a one-time, intrathecally-administered, AAV gene therapy for treating spinocerebellar ataxia type 3. The company has collaboration and license agreements with Bristol Myers-Squibb Company; Gen-X; and Synpromics Limited. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
IPO Year: 2014
Exchange: NASDAQ
Website: uniqure.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/1/2025 | $38.00 | Buy | Chardan Capital Markets |
| 12/10/2024 | Outperform → Strong Buy | Raymond James | |
| 10/10/2024 | $20.00 | Outperform | Raymond James |
| 2/29/2024 | $8.00 | Buy → Neutral | Goldman |
| 12/19/2023 | $52.00 → $10.00 | Buy → Neutral | Mizuho |
| 3/17/2022 | $40.00 | Neutral → Buy | UBS |
| 12/17/2021 | $75.00 → $58.00 | Strong Buy → Outperform | Raymond James |
| 10/27/2021 | $66.00 | Outperform | William Blair |
| 7/27/2021 | $78.00 → $81.00 | Outperform | Credit Suisse |
8-K - uniQure N.V. (0001590560) (Filer)
8-K - uniQure N.V. (0001590560) (Filer)
SCHEDULE 13G - uniQure N.V. (0001590560) (Subject)
10-Q - uniQure N.V. (0001590560) (Filer)
8-K - uniQure N.V. (0001590560) (Filer)
DEFA14A - uniQure N.V. (0001590560) (Filer)
DEF 14A - uniQure N.V. (0001590560) (Filer)
PRE 14A - uniQure N.V. (0001590560) (Filer)
8-K - uniQure N.V. (0001590560) (Filer)
10-K - uniQure N.V. (0001590560) (Filer)